| --- |
| title: "House Oversight: Estate Documents (Nov 12) (HOUSE_OVERSIGHT_020992)" |
| source: "House Oversight: Estate Documents (Nov 12)" |
| sourceUrl: "https://www.justice.gov/epstein" |
| date: "2026-01-01" |
| category: "House Oversight" |
| eftaNumber: "HOUSE_OVERSIGHT_020992" |
| ocrPages: 1 |
| ocrChars: 2162 |
| ocrElapsed: 0.0 |
| parseTier: "external-legacy" |
| engine: "engine undisclosed (ep-nov-12.greg.technology mirror)" |
| externalSource: "greg-ep-nov-12" |
| externalLicense: "not granted" |
| externalCredit: "ep-nov-12.greg.technology" |
| externalUrl: "https://ep-nov-12.greg.technology" |
| --- |
| |
| Restructure Medicare & Medicaid: Economic Factors— |
| Poor Information & Lack of Price Transparency |
| Make it Harder for Consumers to "Comparison Shop" |
| Patients are at a healthcare information disadvantage in two respects: |
| • Lack of transparency: |
| > It's harder for consumers to compare prices of healthcare services from |
| different healthcare providers than in other consumer markets given the |
| complexity of healthcare market. |
| > With employer- / government-subsidized insurance, many patients are |
| 'locked in' with their insurance plans that do not incentivize "shopping |
| around." |
| • Knowledge gap: |
| > Unlike other markets where consumers tend to use their own information and |
| preferences, consumers depend more on the advice and guidance of |
| physicians or other healthcare suppliers. |
| > Unlike other "merchandise," healthcare is literally of life-and-death |
| importance to consumers, making risk aversion - and price |
| insensitivity - higher. This price insensitivity is exacerbated because the |
| consumer, in effect, gets it at a discounted price anyway. |
| Source: 1) Accounting for the cost of US healthcare, McKinsey Global Institute |
| www.kpcb.com |
| USA Inc. | What Might a Turnaround Expert Consider? 301 |
| Restructure Medicare & Medicaid: Economic Factors— |
| Consumers Increasingly Demand Expensive Treatment and Are Able to |
| Pay for it With Government Subsidies |
| Total High-End Surgeries up 50x from 1970-2004, Driven by Medical |
| Advancements + Consumer Ability to Spend Assisted by Government Payments |
| # of Patients (Aged 50+) Undergoing Typical Costs per |
| Advanced Procedures in USA |
| Procedure ($) |
| 1970 |
| 2004 |
| Coronary Procedures |
| Angioplasty / Stent |
| Implantation |
| Pacemaker / ICD^ |
| Bypass |
| <20,000 |
| 1.1 million |
| $12,000 |
| <10,000 |
| <10,000 |
| Dialysis Procedures |
| <10,000 |
| 350,000 |
| 220,000 |
| 480,000 |
| $15-34,000 |
| $28,000 |
| $24-72,000 per |
| year |
| Joint Replacement Procedures |
| Hip |
| Knee |
| 3 www.kpcb.com |
| <20,000 |
| -- |
| 390,000 |
| $12,500 |
| 440,000 |
| $12,500 |
| Note: 1) /CD is Implantable Cardioverter Defibrillator, which is similar to a pacemaker but for a heart rhythm that beats too fast. |
| Cost of procedure approximated by Medicare reimbursement. |
| USA Inc. | What Might a Turnaround Expert Consider? 302 |
| HOUSE |
| _OVERSIGHT_020992 |
|
|
